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ABSTRACT
This study was designed to determine the percentage of asthma-related emergency department (ED) visits made by patients
who recently ran out of their inhaled short-acting beta-agonists or inhaled corticosteroids and to characterize this understudied
patient population. A secondary analysis was performed of data from four ED-based multicenter studies of acute asthma during
1996–1998 (n  64 EDs). In each study, consecutive adult patients, aged 18–54 years, with acute asthma underwent a
structured interview that assessed running out of inhaled medications. The analytic cohort comprised 1095 adults. Overall, 324
patients (30%; 95% confidence interval [CI], 27–32%) ran out of either of their inhaled beta-agonists or inhaled corticosteroids
during the week before their index ED visit; 311 (28%; 95% CI, 26–31%) ran out of inhaled beta-agonists per se. Among a
subset of 518 patients on inhaled corticosteroids, 55 patients (11%; 95% CI, 8–14%) ran out of inhaled corticosteroids. In the
multivariable model, predictors of running out of an asthma medication were male sex, non-Hispanic black race, Hispanic
ethnicity, no insurance, lower household income, and use of EDs as the preferred source of asthma prescriptions (all p  0.05).
Among patients who ran out of medications, 49% (95% CI, 43–55%) ran out of inhaled beta-agonists and 72% (95% CI,
58–84%) ran out of inhaled corticosteroids, before onset of their acute asthma symptoms. In 1095 adult ED patients with acute
asthma, we found that 30% ran out of their inhaled asthma medications before the ED visit. Asthma patients who ran out of
medications had sociodemographic characteristics that may help with identification of preventable ED visits. Multifaceted
strategies needed to ensure optimal use of inhaled medications are warranted.
(Allergy Asthma Proc 35:e42–e50, 2014; doi: 10.2500/aap.2014.35.3747)
A
sthma is an important public health problem in
the United States. Asthma prevalence remains at
historically high levels, affecting 26 million Americans
in 2010.
1 Recent national estimates indicate that there
are 2 million asthma emergency department (ED) visits
each year.
1–3 This patient population is a cause for
concern because most asthma-related ED visits repre-
sent a treatment or maintenance failure
4,5 and are
deemed to be preventable through longitudinal disease
management undertaken by both medical providers
and the patient.
6,7 Furthermore, ED visits impose a
heavy economic burden on health care spending as
much as five times more per visit than a typical out-
patient office visit for asthma.
8
Systematic evaluation of ED patients with acute
asthma could identify reasons for the ED visits that go
beyond acute asthma severity. For example, nonadher-
ence with treatment is a contributor to the poor control
in this patient population.
9,10 One form of nonadher-
ence is “running out” of inhaled medications, such as
inhaled -agonists or inhaled corticosteroids. Studies
have indicated that asthma patients commonly and
significantly overestimate the remaining amount of
asthma medication in metered-dose inhalers (MDIs).
11–14
Furthermore, with continued use of an MDI beyond
the recommended number of doses, active medication
delivery per actuation becomes inconsistent and un-
predictable.
15 A potential consequence of running out
of inhaled medications is suboptimal disease control
and ED visits for acute asthma. Despite this likely
clinical relevance for a major public health burden
(asthma-related ED visits), there have been no studies,
to date, that characterize this important patient popu-
lation.
To address these gaps in current knowledge, we
analyzed the data from several multicenter ED-based
studies. The two objectives of the present analysis were
(1) to determine the percentage of asthma-related ED
visits made by adults who ran out of their inhaled
short-acting -agonists or inhaled corticosteroids be-
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e42 May–June 2014, Vol. 35, No. 3fore the ED visit and (2) to identify characteristics of
this understudied patient population. A better under-
standing these patients could help to improve their
asthma management, close the chasms in asthma care,
and reduce health care spending.
METHODS
Study Design and Participants
This study was a secondary analysis of the data from
four ED-based multicenter prospective studies of acute
asthma that were performed during 1996–1998, as part
of the Multicenter Airway Research Collaboration.
16–22
Multicenter Airway Research Collaboration is part of the
Emergency Medicine Network,
23 a research collabora-
tion with 200 participating EDs. Using a standard-
ized protocol, investigators at 64 North American EDs
in 22 U.S. states and 4 Canadian provinces enrolled
patients 24 hr/day for a median of 2 weeks. The Insti-
tutional Review Board at each of the 64 participating
hospitals approved the study, and informed consent
was obtained for all participants. All patients were
managed at the discretion of the treating physician.
Inclusion criteria were adults aged 18–54 years with
a history of asthma before the index ED visit and the
ability to give informed consent. For the current anal-
ysis, patients were excluded if they did not use inhaled
short-acting -agonists during the past 4 weeks before
their index ED visit or medication ran out status was
not documented.
Data Collection
The ED interview assessed patient demographics,
socioeconomic status, asthma history, chronic asthma
medications, medication ran-out status, and details of
the current asthma exacerbation, including duration of
symptoms. Data on respiratory rate, oxygen saturation,
peak expiratory flow, ED course, and ED disposition
were obtained by chart review. Follow-up interviews
were performed by telephone 2 weeks after the ED
visit. All forms were reviewed by site investigators
before submission to the Emergency Medicine Net-
work Coordinating Center in Boston, MA, where they
underwent further review by trained personnel and
then double data entry.
Median household income was estimated using
home zip code. Peak expiratory flow was expressed as
percentage of predicted value based on age, sex,
height, and race/ethnicity.
24 Changes in peak expira-
tory flow are expressed as the absolute change in per-
cent predicted (e.g., an improvement from 40% pre-
dicted to 70% predicted would be expressed as a
change of 30%). Relapse was defined as any urgent
visit to an ED or clinic for worsening of asthma during
2-week follow-up.
Outcome Measures
The primary outcome measure was running out of
an inhaled asthma medication, either inhaled short-
acting -agonists or inhaled corticosteroids, during the
week before the index ED visit. Then, we further cat-
egorized this outcome by the medication class that ran
out: inhaled short-acting -agonists or inhaled cortico-
steroids.
Statistical Analysis
Summary statistics at the patient levels are presented
as proportions (with 95% confidence intervals [CIs]),
means (with SDs), and medians (interquartile range).
The unadjusted associations between patient character-
istics and ran-out status were analyzed using chi-
squared test, unpaired t-test, and Kruskal-Wallis test,
as appropriate.
Multivariable logistic regression was performed to
identify demographic and chronic asthma factors asso-
ciated with the likelihood of running out of the medi-
cation, compared with not running out of the medica-
tion. Model variables were selected a priori based on
clinical plausibility. These selected variables included
age, sex, race/ethnicity, insurance, estimated house-
hold income, primary care provider status, hospitaliza-
tion for asthma in the past year, and patient’s preferred
source of asthma medication prescriptions. We tested
for two-way interaction by multiplying the two factors
of interest and including an interaction term in the final
multivariable model if the interaction was statistically
significant (p  0.05).
We also examined the distributions of days from
running out of each medication to the onset of the
asthma exacerbation, stratified by medication class. All
analyses used SAS Version 9.3 (SAS Institute, Cary,
NC) and all odds ratios are presented with 95% CI.
RESULTS
Of 1847 adult patients with acute asthma, we ex-
cluded patients who reported that they were not on
inhaled short-acting -agonists (n  260) and those
with ran-out status not documented (n  492). After
these exclusions, the analytic cohort comprised 1095
ED patients for acute asthma. The analytic cohort and
patients with ran-out status not documented were sim-
ilar in age and sex (p  0.05); but the analytic cohort
had a lower proportion of black race (43%versus 54%;
p  0.001). Of the 1095 ED patients, 324 patients (30%;
95% CI, 27–32%) ran out of either of their inhaled
short-acting -agonists or inhaled corticosteroids dur-
ing the week before their index ED visit.
Unadjusted analysis of the associations between pa-
tient characteristics and ran-out status are shown in
Table 1. Patients who ran out of their inhaled asthma
medications were on average younger and had a sig-
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e44 May–June 2014, Vol. 35, No. 3nificantly higher proportion of male sex and non-His-
panic black race compared with those who did not run
out of medication (all, p  0.01). Markers of socioeco-
nomic status (e.g., estimated household income) were
also associated with running out of an inhaled medi-
cation (p  0.003). Similarly, the proportion of patients
with insurance or a primary care provider was signif-
icantly lower in those who ran out of their medications
(both, p  0.001).
With regard to chronic asthma history, there were
few significant differences between the groups. How-
ever, the number of asthma ED visits in the past year
and the proportion of patients who reported the ED as
their preferred source of asthma medication prescrip-
tions were higher in those who ran out of their medi-
cations (both, p  0.001).
Although initial respiratory rate and peak expiratory
flow of the two groups did not differ significantly, the
patients who ran out of their inhaled medications had
a higher proportion of acute onset of asthma exacerba-
tion (i.e., 24 hours), compared with those who did not
(p  0.001). Additionally, those who ran out had a
lower proportion of hospital admission from the ED
(p  0.03) and relapse within 2 weeks after ED dis-
charge (p  0.001).
Table 2 summarizes patient characteristics according
to inhaled medication. Among 1095 ED patients, 311
patients (28%; 95% CI, 26–31%) ran out of their inhaled
short-acting -agonists before the index ED visit.
Among 518 patients on inhaled corticosteroids, 55 pa-
tients (11%; 95% CI, 8–14%) ran out of this medication.
In addition, among 518 patients on inhaled short-act-
ing -agonists and inhaled corticosteroids, 42 patients
(8%; 95% CI, 6–11%) ran out of both medications.
Across the medication subgroups, the proportion of
non-Hispanic black race, lower household income, no
insurance or primary care provider, current smoking,
and use of ED as the preferred source of asthma pre-
scriptions was significantly higher in patients who ran
out of their asthma medications (all, p  0.05).
Multivariable logistic regression modeling was per-
formed to address the interrelations between many of
these factors (Table 3). Overall, male sex, non-Hispanic
black race, Hispanic ethnicity, no insurance, lower
household income, and use of ED as the preferred
source of asthma prescriptions were significantly asso-
ciated with a higher chance of running out of their
inhaled asthma medications (all, p  0.05). Most nota-
bly, non-Hispanic black patients and patients with no
insurance had approximately two times higher odds of
running out of their medications. Furthermore, across
the subgroup analyses, no insurance remained as a
significant predictor of running out of inhaled medica-
tions.
Figures 1 and 2 depict the days from running out of
medications to the onset of acute asthma symptoms.
Interestingly, among those who ran out of their inhaled
short-acting -agonist, 49% (95% CI, 43–55%) ran out
before the onset of symptoms. Among those who ran
out of their inhaled corticosteroids, 72% (95% CI, 58–
84%) ran out before the onset of symptoms.
DISCUSSION
Our prospective cohort of 1095 ED patients with
acute asthma showed that 30% of patients ran out of
their asthma medications during the week before the
ED visit. We found that male sex, non-Hispanic black
race, markers of low socioeconomic status, and use of
ED as the preferred source of asthma prescriptions
were independently associated with a higher chance of
running out of an inhaled asthma medication.
Mechanisms of Running out of Asthma
Medications
Medication nonadherence in asthma is well recog-
nized, with adherence rates generally ranging from 30
to 70%.
25,26 The present study extends prior research
by focusing on asthma-related ED visits made by pa-
tients who ran out of their inhaled medications. Defin-
ing the magnitude of this problem, along with risk
factors, is essential to develop and implement targeted
strategies in this high-risk population. There are many
potential reasons why a significant proportion of pa-
tients ran out of their asthma medications before the
ED visit. For example, an increased use of quick reliev-
ers during asthma exacerbations may have resulted in
“running out of medication.” However, about one-half
of these ED patients ran out of their inhaled short-
acting -agonists (and 70% ran out of their inhaled
corticosteroids) before the onset of asthma exacerba-
tion symptoms. Therefore, it is difficult to postulate
that this mechanism fully explains the high percentage
of adult ED patients who present to the ED with acute
asthma.
Alternatively, our data indicate that personal health
behavior is significantly associated with this form of
medication nonadherence; indeed, 60% of patients
who ran out of their medications reported that they
used EDs as the preferred source of asthma prescrip-
tions. Furthermore, our findings, a shorter duration of
asthma exacerbation symptoms and a lower rate of
hospitalizations among these patients, might suggest
heavier reliance on episodic symptom treatment in the
ED for milder asthma exacerbations.
In addition, other nonbiological factors, such as less
asthma education, a lack of personal action plans, and
limited access to ambulatory health care and asthma
specialists may contribute.
27 After the dissemination of
National Asthma Education and Prevention Program
guidelines in 1991, 1997, and 2007, the literature
showed increases in the use of preventive asthma med-
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28,29 However, important aspects of the guide-
lines, such as asthma education and action plans, re-
main widely underused.
30 In addition, our national
survey of 177 asthma centers indicated a suboptimal
coordination of care between EDs and asthma cen-
ters,
31 which is particularly unfortunate given prior stud-
ies showing that interventions and treatment by asthma
specialists are associated with decreased asthma-related
ED visits
32,33 and that dedicated asthma centers have
shown promise in reducing ED use.
34,35 Although the
ED-to-specialist linkage has not materialized, these prior
studies support optimism that adverse asthma outcomes
can be prevented and the personal and public health
burden can be reduced.
Underestimation of Patients Who Ran out of
Medications
Although our data were gathered prospectively,
questionnaire items regarding medication ran-out sta-
tus were self-reported and there was no attempt to
verify the accuracy of the stated information. However,
prior studies have reported that asthma patients over-
estimate the remaining amount of asthma rescue med-
ications in MDIs; indeed, up to 40% of patients be-
lieved that they were taking their asthma medications
when they activate an empty or nearly empty MDI.
11,12
Therefore, our study may have underestimated the
magnitude of the asthma morbidity caused by running
out of the inhaled medication.
With the current design of MDIs, it is not possible for
an MDI to cease delivering a spray when the active
drug has been depleted. MDIs continue to deliver a
spray, which may not be within the labeled specifica-
tions for the active drug; the amount of drug in those
additional actuations becomes inconsistent and unpre-
dictable, with the amount of active drug eventually
becoming negligible, a phenomenon known as “tail-
off.”
15 Additionally, a growing number of literature
has shown high error rates in patient’s ability to gauge
doses remaining in their MDIs with various methods,
Table 3 Multivariable model of factors associated with running out of inhaled asthma medication, overall
and according to medication type
Variables* Inhaled Medication Inhaled Short-Acting
-Agonists
Inhaled Corticosteroids
Odds Ratio
(95% CI)
p Value Odds Ratio
(95% CI)
p Value Odds Ratio
(95% CI)
p Value
Age, decile (yr) 0.86 (0.75–1.00) 0.052 0.86 (0.74-1.00) 0.049 1.01 (0.74–1.39) 0.94
Male sex 1.44 (1.05–1.97) 0.02 1.54 (1.12–2.12) 0.08 0.94 (0.60–1.10) 0.86
Race/ethnicity 0.01 0.02 0.04
Non-Hispanic white 1 (reference) 1 (reference) 1 (reference)
Non-Hispanic black 2.12 (1.35–3.32) 1.99 (1.26–3.13) 2.86 (0.93–8.82)
Hispanic 1.68 (1.02–2.79) 1.53 (0.92–2.56) 2.96 (0.89–9.79)
Other 2.39 (0.77–7.44) 2.41 (0.77–7.51) 7.64 (1.10–53.3)
Insurance status 0.03 0.03 0.008
Private 1 (reference) 1 (reference) 1 (reference)
Medicaid 1.40 (0.94–2.09) 1.43 (0.95–2.15) 1.84 (0.74–4.59)
Other public 1.26 (0.75–2.12) 1.16 (0.68–1.99) 1.55 (0.51–4.69)
None 1.58 (1.05–2.37) 1.58 (1.05–2.38) 2.21 (1.36–8.05)
Estimated household income
(odds ratio per 10,000–
U increase)
0.87 (0.75–0.99) 0.04 0.88 (0.77–1.02) 0.08 0.81 (0.60–1.10) 0.18
Has primary care provider 1.05 (0.71–1.55) 0.82 1.02 (0.69–1.52) 0.92 0.76 (0.32–1.82) 0.54
Admitted for asthma in past
year
0.87 (0.64–1.19) 0.38 0.88 (0.64–1.20) 0.41 0.54 (0.29–1.02) 0.06
ED as preferred source of
asthma prescriptions
1.88 (1.31–2.68) 0.001 1.87 (1.30–2.69) 0.001 1.23 (0.57–2.68) 0.60
Bold-face type results are statistically significant.
*The multivariable model adjusts for the following patient and hospital characteristics: age, sex, race/ethnicity, insurance
status, estimated household income, primary care provider status, hospital admission for asthma in past year, and ED as
preferred source of asthma prescriptions. Testing for interactions among sex, insurance status, and primary care provider status
did not indicate the presence of an effect modification; therefore, these interaction terms were not included in the final models.
ED  emergency department.
Allergy and Asthma Proceedings e47such as the weight of the inhaler, the force, sounds, and
taste of the actuation.
14,36 In addition, the only Food
and Drug Administration–approved approach is for
patients to keep track of doses as they use them; how-
ever, demanding this practice is impractical.
13 The in-
correct use of asthma medications would likely lead to
poor control of asthma symptoms and, potentially, ED
visits for acute asthma. These data not only under-
score the importance of patient education on the
optimal use of asthma medications but also empha-
size the importance of reliable means to monitor the
contents of their MDIs.
13 Indeed, the latter was sup-
ported by the Food and Drug Administration’s
Guidance for Industry to integrate dose-counting
mechanisms into MDIs.
37
Disparities in Prevalence of Running out of
Medications
We were also struck by the racial/ethnic and so-
cioeconomic disparities for this type of medication
nonadherence. Asthma patients at highest risk of
running out of medications were non-Hispanic black
patients and had no insurances and lower household
income. These observations are consistent with prior
studies showing less self-management education,
lower inhaled corticosteroid use, and more limited
access to preventive and specialist care among U.S.
minority populations, which may lead to heavier
reliance on episodic symptom treatment and an in-
creased incidence of emergency asthma care in this
population.
38–41
Figure 1. Days from running out of inhaled short-
acting -agonists to beginning of symptoms.
Figure 2. Days from running out of inhaled cortico-
steroids to beginning of symptoms.
e48 May–June 2014, Vol. 35, No. 3Recent research has advanced our understanding of
medication nonadherence in chronic conditions; it is a
common problem reflecting a failure of the health care
system and is understood as a variable behavior with
intentional and unintentional causes.
42 Intentional non-
adherence is the product of a decision informed by beliefs
and preferences; unintentional nonadherence is linked to
limitations in capacity of resources. Given that the causes
of nonadherence are likely complex and multilevel,
clinical strategies to address these disparities must
therefore be multifaceted and target many aspects of
asthma care.
43,44 The strategies should address the per-
ceptual barriers limiting patients’ motivation to persist
with the inhaled medications by improving patient–
provider communication about patient preference,
asthma beliefs, and barriers to care. In addition, it is
imperative to address the practical barriers influencing
the ability to adhere to the treatment regimen (e.g., not
running out of inhaled medications) by improving ac-
cess to longitudinal preventive care and refining
asthma medication devices. For example, inclusion of
dose-counting mechanisms as a standard feature of
every MDI—one of the currently available measures—
may help to ensure that patients receive accurate me-
tered doses of asthma medication and to provide reli-
able information for when to replace an MDI,
11,45
thereby improving optimal use of medications and
potentially reducing preventable ED visits for acute
asthma.
Limitations
Our study has several potential limitations. First, we
analyzed multicenter data from 15 years ago; there-
fore, our ability to extrapolate these inferences to the
current asthma patient population may be limited.
However, we note that, to date, there have been no
other studies on ED patients who run out of their
inhaled asthma medications. Therefore, we believe that
our older data represent the best information available
and will be helpful in health policy discussions about
this underrecognized problem. Moreover, our data will
assist the design of future studies to further explore
this important issue in current asthma patients. Sec-
ond, we did not analyze the outpatient management of
these patients presenting with acute asthma, such as
asthma self-management education and access to spe-
cialist care; these factors probably are associated with
medication ran-out status. Furthermore, we have only
sparse data on psychosocial problems and barriers to
health care access of this high-risk population; these
are areas for future investigation. Finally, the EDs that
composed this sample were predominantly urban,
teaching hospitals. This may make these results less
generalizable to other clinical settings (e.g., community
hospitals). However, urban areas have disproportion-
ately high asthma morbidity, and it is in precisely this
population for which targeted preventive measures are
most urgently needed.
CONCLUSION
By using interview data from 1095 adult ED patients
with acute asthma, we found that 30% of patients ran
out of their asthma medications before their ED visit.
We also showed that male sex, non-Hispanic black
race, markers of low socioeconomic status, and use of
ED as the preferred source of asthma prescriptions
were significantly associated with a higher chance of
running out of their asthma medications. Our ability to
extrapolate these results to the current asthma patient
population may be limited. However, for researchers,
our data represent the best information available and
may assist in the design of future studies to further
explore this understudied topic—in the current asthma
population. Additionally, for policy makers, our find-
ings underscore the importance of multifaceted strate-
gies—e.g., inclusion of dose-counting mechanisms as a
standard feature of every MDI—to curb the asthma-
related public health burden in an already-stressed
health care system.
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